Showing 521-530 of 3076 results for "".
Journal Club: Biologics for Young Children
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databasePros and Cons of DTC Advertising
https://practicaldermatology.com/topics/practice-management/pros-and-cons-of-dtc-advertising/18569/Hilary Baldwin, MD and James Q. Del Rosso, DO sit down with Derm Insider Host Neal Bhatia, MD to weigh the pros and cons of direct-to-consumer advertising on patients. They agree that if done well and with a primary focus on disease state rather than a specific drug, these ads can encourage patientsVitiligo: Understanding Your Options
https://practicaldermatology.com/youngmd-connect/wrap-ups/vitiligo-understanding-your-options/29890/Showing up is half the battle, it has often been said. According to dermatologist Nanette Silverberg, MD, FAAP, FAAD, chief of pediatric dermatology at Mount Sinai Health System in New York, that adage applied to the attendees at a recent YoungMD Connect virtual session featuring two expert presentaSelling Skin Care in Your Practice
https://practicaldermatology.com/topics/practice-management/selling-skin-care-in-your-practice/19294/While selling skin care products in your practice may seem like it has some disadvantages, Joel Schlessinger MD believes it's worth the extra work. During this video, Joel Schlessinger MD explains why he decided to sell products in his practice. Overall, he finds that selling items he recommends toOn Mentorship, Open- Mindedness, and Fulfillment: A Chat with Dr. Peter Lio
https://practicaldermatology.com/youngmd-connect/wrap-ups/on-mentorship-open-mindedness-and-fulfillment-a-chat-with-dr-peter-lio/29892/Young MD Connect recently hosted a mentorship session with Dr. Peter Lio to learn from a practicing professional in the field of dermatology in a relaxed “Ask Me Anything” setting. Dr. Lio is a clinical assistant professor of dermatology and pediatrics at Northwestern University and the founding dirScientifically Speaking: The Truth About Skincare
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-the-truth-about-skincare/19876/From workhorse ingredients like antioxidants and retinol to newer molecules that address pigmentation and aging, there is a lot of noise in the skincare marketplace. And that's without talking about "natural" formulations. Joel L. Cohen, MD gets to the heart of the science, in a conversation with DeNoah Worcester 2024: Dr. Gottlieb on Psoriatic Arthritis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gottlieb-psoriatic-arthritis/24594/Alice Gottlieb, MD, PhD, summarizes her lecture on the critical role of the dermatologist in preventing disability due to psoriatic arthritis at the 2024 Noah Worcester Dermatological Society meeting.Exosome Therapy: Explained
https://practicaldermatology.com/conferences/scale-2023/exosome-therapy-explained/20200/Jane Yoo, MD, explains exactly what exosomes are and highlights some current therapeutic uses for exosome therapy including treating hair loss and reducing redness after laser skin resurfacing.Finally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."